3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

NCT00081276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions

DRUG: triapine
DRUG: cisplatin
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)